GlassScriptPhysician profile
Abel T Yimer
NPI 1053767392
$1,267.16
in general payments reported to CMS, 2019-2025
17 companies · $277 in 2025
The $277 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.87 · 2022: $564 · 2023: $166 · 2024: $208 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $650.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $218.20 | 2022-2023 | Gvoke Hypopen |
| Medtronic, INC. | $216.53 | 2023-2024 | Minimed 780g |
| Dexcom, INC. | $159.61 | 2024-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $139.14 | 2022 | |
| Insulet Corporation | $116.97 | 2025 | Omnipod |
| Abbott Laboratories | $82.59 | 2025 | Freestyle Libre 3 |
| Mannkind Corporation | $65.23 | 2022 | |
| Amgen INC. | $53.21 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.99 | 2022 | |
| Allergan, INC. | $31.64 | 2019 | |
| Lilly USA, LLC | $29.72 | 2022 | |
| Merck Sharp & Dohme LLC | $22.74 | 2023 | Steglujan, Steglatro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.23 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.69 | 2022 | |
| Amryt Pharma Holdings LTD | $15.24 | 2023 | Myalept |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $15.02 | 2022 | |
| Intuity Medical INC | $12.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abel Yimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.